Hepatorenal Syndrome Treatment Guidelines

Introduction to Hepatorenal Syndrome Management

• The American Association for the Study of Liver Diseases recommends the use of midodrina and octreotida with albumin for the treatment of hepatorenal syndrome type 1, especially in cases where terlipresina is not available, with midodrina 7.5 mg orally three times a day and octreotida 100-200 μg subcutaneously three times a day 1, 2
• The administration of albumin with antibiotics in spontaneous bacterial peritonitis is crucial for preventing hepatorenal syndrome, with a dose of 1.5 g/kg body weight at diagnosis, followed by 1 g/kg on day 3, reducing the incidence of hepatorenal syndrome type 1 from 30% to 10% and mortality from 29% to 10% compared to cefotaxime alone 3, 4

Treatment of Hepatorenal Syndrome Type 1

• The European Association for the Study of the Liver suggests that terlipresina plus albumin is the first-line treatment for hepatorenal syndrome type 1, with terlipresina 0.5-1 mg IV every 4-6 hours and albumin 1 g/kg body weight on day 1 (maximum 100 g), followed by 20-40 g/day, until complete response or for a maximum of 14 days 1, 2
• The International Club of Ascites recommends that albumin should be avoided or discontinued in patients with head trauma (associated with damage), anasarca (severe volume overload), or hemorrhagic shock (preferring isotonic crystalloids) 5

Prevention of Hepatorenal Syndrome

• The administration of albumin with antibiotics in spontaneous bacterial peritonitis is fundamental for preventing hepatorenal syndrome, with a dose of 1.5 g/kg body weight at diagnosis, followed by 1 g/kg on day 3, reducing the incidence of hepatorenal syndrome type 1 from 30% to 10% and mortality from 29% to 10% compared to cefotaxime alone 3, 4
• The American Journal of Kidney Diseases recommends that patients with high bilirubin levels (≥68 μmol/L or 4 mg/dL) or high creatinine levels (≥88 μmol/L or 1 mg/dL) are at higher risk of developing hepatorenal syndrome and may benefit from albumin administration 3, 4

Alternative Therapies

• The American Association for the Study of Liver Diseases does not recommend replacing albumin with starch solutions (associated with damage in patients at risk of acute kidney injury) or hydroxyethyl starch (no beneficial effect on circulatory function in spontaneous bacterial peritonitis) 3, 4, 5
• The European Association for the Study of the Liver suggests that crystalloids or artificial colloids in spontaneous bacterial peritonitis have not been shown to replace albumin 3, 4

Diagnostic Criteria and Treatment Options for Hepatorenal Syndrome

Diagnostic Criteria

• The diagnosis of hepatorenal syndrome requires cirrhosis with ascites, serum creatinine >1.5 mg/dL, no improvement of serum creatinine after diuretic withdrawal and volume expansion with albumin, absence of shock, no current or recent treatment with nephrotoxic drugs, and absence of parenchymal renal disease 6, 7, 8
• The American Association for the Study of Liver Diseases recommends using AKI staging for HRS diagnosis, with stages defined by increase in creatinine ≥0.3 mg/dL up to 2-fold of baseline, 2-fold to 3-fold of baseline, or >3-fold of baseline or creatinine >4 mg/dL with acute increase ≥0.3 mg/dL or initiation of renal replacement therapy 7

Classification of HRS

• Type 1 HRS is characterized by rapidly progressive renal impairment with increase in serum creatinine ≥100% from baseline to a level >2.5 mg/dL in less than 2 weeks, and poor prognosis with median survival of approximately 1 month if untreated 6, 7, 9
• Type 2 HRS is characterized by stable or less progressive impairment in renal function, with a more chronic course and better survival compared to Type 1 HRS 6, 7, 8

Treatment Options

• The first-line treatment for Type 1 HRS is terlipressin plus albumin, with an initial dose of 1 mg IV every 4-6 hours, increased stepwise to maximum 2 mg every 4 hours if serum creatinine doesn't decrease by at least 25% after 3 days, and continued until complete response or maximum 14 days for partial response 10, 11
• Alternative treatments for Type 1 HRS include midodrine plus octreotide plus albumin, and norepinephrine plus albumin, which requires an ICU setting 8, 9, 10, 11
• Liver transplantation is the definitive treatment for both Type 1 and Type 2 HRS, with expedited referral recommended for Type 1 HRS and post-transplant survival rates approximately 65% 9, 11

Prevention of HRS

• Albumin infusion with antibiotics when treating spontaneous bacterial peritonitis can help prevent HRS 7, 9
• Norfloxacin (400 mg/day) can reduce HRS incidence in advanced cirrhosis 9, 11
• Pentoxifylline (400 mg three times daily) can prevent HRS in severe alcoholic hepatitis 9, 11
• Avoiding nephrotoxic drugs in patients with advanced cirrhosis is also recommended 7, 8

Hepatorenal Syndrome Treatment Guidelines

First-Line and Alternative Treatments

• The American Association for the Study of Liver Diseases recommends the combination of midodrine plus octreotide plus albumin as an alternative treatment when terlipressin is unavailable, with midodrine started at 7.5 mg orally three times daily, titrated up to a maximum of 12.5 mg three times daily, octreotide at 100-200 μg subcutaneously three times daily, and albumin at 10-20 g IV daily for up to 20 days 12
• The use of midodrine/octreotide/albumin can be administered outside the ICU and even at home, and has shown reduced mortality in a retrospective study (43% versus 71% in controls, P < 0.05) 12

Third-Line Options and Critical Considerations

• Norepinephrine plus albumin is an effective alternative but requires ICU admission, with norepinephrine at 0.5-3.0 mg/hour IV to increase mean arterial pressure by 15 mm Hg, and has a success rate of 83% in reversing type 1 HRS in pilot studies 12
• The combination of midodrine plus octreotide plus albumin should not use octreotide as monotherapy, as it requires midodrine to be effective, and two studies have definitively shown octreotide alone provides no benefit 12
• Monitoring serum creatinine every 2-3 days is recommended to assess treatment response, with complete response defined as serum creatinine ≤1.5 mg/dL on two occasions 12

Albumin Administration in Hepatorenal Syndrome

Initial Dosing Protocol

• The European Association for the Study of the Liver recommends administering albumin at 1 g/kg body weight on day 1, with a maximum dose of 100 g, followed by 20-40 g/day in combination with vasoconstrictors, continuing until complete response or for a maximum of 14 days 13
• Albumin should be administered as a 20% or 25% solution intravenously 14

Critical Prerequisites Before Starting Albumin

• The American Association for the Study of Liver Diseases suggests withdrawing all diuretics for at least 2 consecutive days before initiating albumin therapy 13
• The International Club of Ascites recommends performing volume expansion with albumin 1 g/kg for 2 consecutive days to exclude pre-renal AKI 13
• The European Society of Gastrointestinal Endoscopy advises ruling out other causes of kidney injury, such as shock, nephrotoxic drugs, proteinuria, and microhematuria, before starting albumin therapy 13

Combination with Vasoconstrictors

• The American College of Gastroenterology states that albumin is never used alone for hepatorenal syndrome treatment and must be combined with vasoconstrictors 13

Dosage and Administration

• The maximum dose of albumin on day 1 should not exceed 100 g, as higher doses are associated with worse outcomes, possibly due to fluid overload 13, 14

Octreotide Mechanism and Clinical Monitoring in Hepatorenal Syndrome

Mechanism of Action

• Octreotide inhibits glucagon—a potent splanchnic vasodilator—thereby reducing splanchnic vasodilation and improving renal perfusion in patients with hepatorenal syndrome (HRS). 15
• Octreotide produces direct splanchnic vasoconstriction, further supporting hemodynamic improvement in HRS. 15
• As a somatostatin analog, octreotide counteracts the pathophysiologic splanchnic blood‑pooling that drives HRS. Clinical evidence supports this dual mechanism. 15

Monitoring During Octreotide‑Based Therapy

• Routine assessment for signs of volume overload (e.g., pulmonary edema, anasarca) is recommended while patients receive octreotide for HRS. 15

Adjunctive Albumin Use

• Albumin infusion is essential for volume expansion and anti‑inflammatory effects when octreotide is employed in HRS management. This recommendation is based on clinical data. 15

Prognostic Impact of Creatinine Reduction

• In HRS patients treated with octreotide, each 1 mg/dL decrease in serum creatinine is associated with an approximate 27 % reduction in mortality risk, indicating a strong prognostic benefit. Evidence derives from the cited clinical study. 15